New Neuralstem Article Is Imminent!
Long Only, Momentum, Deep Value
Seeking Alpha Analyst Since 2013
I'll be delivering a Neuralstem (CUR) article sometime on Monday or Tuesday. I've been wanting to revisit Neuralstem and, in particular, discuss the NSI-566 Phase 2 trial for ALS being conducted currently. This isn't an in-depth article like my previous one. Instead it is more of an update.
My article will recap some useful background information on the trial before explaining why I like some of the information coming from the on-going Phase 2 including comments from a patient currently in the trial. I plan to explain why I believe the trial is poised for a successful outcome.
I do not touch on NSI-189 very much, but I do want to give any readers fair warning that those results are expected sometime soon as well. I believe the Phase 2 ALS trial will continue to generate most of the excitement for Neuralstem in 2014 and that the NSI-189 results could only have a benefit on the share price.
Check back on Tuesday or Wednesday for my blog updates regarding my next in-depth article. I'm putting the finishing touches on it and conducting edits and reviews. I plan to submit the article the following week, around 1/13, and I will go into detail in my blog on Tuesday/Wednesday in case you're interested.
Thanks all! Happy New Year and hopefully we all have a great 2014!!!
Disclosure: I am long CUR, .
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.